Gimme Shelter: OPDP’s 2026 Letters Show There’s No “Shelter” From FDA Scrutiny Targeting DTC Ads That Obscure Risk

Footnotes for this article are available at the end of this page.

Key Takeaways

• The Food and Drug Administration’s Office of Prescription Drug Promotion (“OPDP”) is scrutinizing overall “net impression,” not merely isolated claims. The recent wave of Untitled Letters shows that technically accurate statements may still be misleading if the overall presentation exaggerates benefits, obscures limitations, or minimizes risks.
• Risk disclosures must be as clear, prominent, and consumer-friendly as benefit messaging. OPDP repeatedly criticized promotions that buried, minimized, or incompletely presented safety information — even where materials included references to Important Safety Information or full prescribing information.
• Strict alignment with FDA-approved labeling is essential. Promotional materials should clearly and prominently communicate patient population limitations, co-administration requirements, and other conditions of use. Disclaimers, hyperlinks, or back-page qualifiers will not cure an otherwise misleading message.

---

The Rolling Stones’ 1969 classic, “Gimme Shelter,” famously captures a sense of urgency in the face of looming consequences, a theme that resonates with OPDP in its recent enforcement activity. Over the past six weeks, OPDP has issued a series of Untitled Letters targeting direct-to-consumer (“DTC”) advertising and other promotional materials across products and sponsors.¹ While each FDA correspondence addresses product-specific claims, together they reflect a consistent enforcement framework showing that OPDP is not merely policing discrete statements, but scrutinizing how promotional communications systematically shape consumer perception.

The takeaway is not only that certain claims went too far. It is that across these letters, OPDP identified recurring ways in which promotional materials tilt the balance of information, amplifying benefits while obscuring risks, limitations, or context.

The Violations: A Pattern, Not Isolated Errors

1. Risk Omission and Minimization Remain the Core Concern

Across the recent letters, OPDP consistently identified failures to adequately communicate material risks. These include entire omissions of serious adverse events, as well as presentations that render risk information functionally invisible, through placement, formatting, or incomplete summaries.

Even where materials included references to “Important Safety Information” or full prescribing information, OPDP emphasized that cross-references cannot substitute for substantive disclosure. In several cases, risk information consisted only of headings or partial summaries, which OPDP found insufficient to mitigate misleading impressions.

Beyond omission, FDA also focused on minimization, for example, language reassuring patients that side effects are “normal” or likely to resolve, or risk disclosures presented out of sequence, in dense medical terminology, or with reduced prominence relative to benefit claims.

Risk information must not only be present, but it must be accessible, complete, and comparable in prominence to benefit messaging.

2. Overstatement of Efficacy: Explicit and Implied

Several of the United Letters also reflect concern with efficacy claims that go beyond the supporting evidence. OPDP flagged both express overstatements and more subtle forms of exaggeration, including:

• Selective presentation of favorable endpoints.
• Claims implying broader or more durable benefit than demonstrated.
• Messaging that elevates outcomes without appropriate qualifiers.

Importantly, OPDP’s analysis does not require a statement to be literally false. Rather, claims may be misleading where they create an inflated impression of effectiveness, particularly when presented without context or balanced risk information.

3. Omission of Material Limitations of Use

Another recurring issue is the failure to communicate the specific conditions under which a drug is approved. OPDP repeatedly cited materials that:

• Omitted required co-administration with other therapies.
• Failed to identify defined patient populations.
• Did not disclose line-of-therapy or other limitations.

By presenting broad disease categories or general treatment claims without these constraints, materials conveyed an expanded scope of use outside of the approved labeling. As OPDP noted, qualifying language, particularly when buried or deemphasized, is not sufficient to correct this misimpression.

4. Selective Presentation of Evidence and Incomplete Context

A related theme is the presentation of data or claims without necessary context. OPDP flagged instances where materials:

• Highlighted favorable results without explaining study limitations.
• Omitted comparator information.
• Presented claims without sufficient supporting context.
• Conflating efficacy measures across studies to imply correlation without proper clinical support.

5. Net Impression: The Governing Standard

Across OPDP correspondence issued in this recent six-week period, OPDP returns to a central concept: net impression. The agency evaluates not merely individual statements, but the overall takeaway for a reasonable consumer.

This includes:

• Visual design and imagery.
• Placement and prominence of information.
• Tone and framing of language.

Even where individual elements are technically accurate, OPDP will find a violation if the overall presentation skews perception toward greater benefit, broader use, or lower risk. As one Untitled Letter emphasized, qualifying language in small font or after intervening graphics is “not sufficient to mitigate the misleading impression.”

6. Fair Balance as the Unifying Legal Framework

Underlying all of these themes is the regulatory requirement that promotional materials be truthful, non-misleading, and fairly balanced.

OPDP’s recent letters make clear that fair balance is not a mechanical exercise. It is not enough to include risk information somewhere in the piece. Rather, the agency expects that promotional communications:

• Present risks and benefits with comparable prominence and clarity.
• Avoid language that diminishes the significance of risks.
• Accurately reflect the scope and limitations of the approved labeling.

Failures in any of these areas can render a product “misbranded.”

A Notable Dimension: Biosimilars and Implied Superiority

One of the recent letters highlights an additional layer of concern for biosimilar products. OPDP found that omissions and minimization of risk, combined with broad efficacy messaging, created an impression that the product was safer or more effective than its reference product, a claim fundamentally inconsistent with the biosimilar approval standard.

Because biosimilars are, by definition, not clinically superior, promotional materials that imply superiority raise both general misbranding concerns and issues unique to the biosimilar regulatory framework.

Enforcement Signals: A Coherent Strategy Emerges

Viewed together, these OPDP letters reflect a coordinated enforcement approach:

• Strict alignment with labeling: Promotional claims must track the full specificity of the approved indication, including limitations and conditions of use.
• Holistic evaluation of messaging: OPDP is focused on net impression, not technical compliance.
• Readability and accessibility: Risk disclosures and presentation of data must be understandable to the intended audience, not obscured by complexity or formatting.
• Skepticism of disclaimers: Cross-references, footnotes, and back-page disclosures will not cure a misleading front-end message.

AGG Observations

• Ensure promotional materials reflect the full scope and limits of the approved indication, including patient population and treatment context.
• Present risk information with comparable prominence, clarity, and readability as benefit information.
• Avoid reassuring or minimizing language that could dilute the perception of risk.
• Provide complete and contextualized evidence, not selective or isolated data points.
• Evaluate materials based on overall net impression.
• Use caution when relying on URLs, QR codes, or cross-references for safety information. FDA has not endorsed these as substitutes for substantive disclosure.
• Remember that promotional claims may be truthful in isolation, but misleading in context, if the overall presentation creates an inaccurate net impression. Present information in a way that allows consumers to understand what the evidence shows and what it does not. Omissions can render otherwise accurate statements misleading.

Conclusion

OPDP’s recent enforcement activity in the DTC area makes clear that the agency is not simply identifying isolated promotional missteps. It is targeting a broader pattern of communications that systematically bias consumer understanding by enhancing perceived benefits while obscuring risks, limitations, or context.

Similar to the warning embedded in “Gimme Shelter,” the current enforcement environment offers little refuge for promotional strategies that run afoul of the law. The message for industry is that there is no shelter from scrutiny where net impression misleads. Companies should treat these letters as a call to reassess internal review processes and prepare for continued, coordinated oversight.

For guidance on these issues, please contact a member of AGG’s Food & Drug team.

 

[1] Read the full Untitled Letters referenced in this article here: https://www.fda.gov/media/192241/download?attachment; https://www.fda.gov/media/192265/download?attachment; https://www.fda.gov/media/192125/download?attachment; https://www.fda.gov/media/191932/download?attachment; https://www.fda.gov/media/191883/download?attachment.